{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

Ebola Virus Research - Ebola Virus Research How is Ebola...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Ebola Virus Research How is Ebola hemorrhagic fever treated? There is no standard treatment for Ebola HF. Patients receive supportive therapy. This consists of balancing the patient’s fluids and electrolytes, maintaining their oxygen status and blood pressure, and treating them for any complicating infections. How is Ebola hemorrhagic fever prevented? The prevention of Ebola HF in Africa presents many challenges. Because the identity and location of the natural reservoir of Ebola virus are unknown, there are few established primary prevention measures. If cases of the disease do appear, current social and economic conditions often favor the spread of an epidemic within health-care facilities. Therefore, health-care providers must be able to recognize a case of Ebola HF should one appear. They must also have the capability to perform diagnostic tests and be ready to employ practical viral hemorrhagic fever isolation precautions, or barrier nursing techniques. These techniques include the wearing of protective clothing, such as masks, gloves, gowns, and goggles; the use of infection-control measures, including complete equipment sterilization; and the isolation of Ebola HF patients from contact with unprotected persons. The aim of all of these techniques is to avoid any person’s contact with the blood or secretions of any patient. If a patient with Ebola HF dies, it is equally important that direct contact with the body of the deceased patient be prevented. CDC has developed a set of tools to meet health-care facilities' needs. In conjunction with the World Health Organization, CDC has developed practical, hospital-based guidelines, entitled Infection Control for Viral Haemorrhagic Fevers In the African Health Care Setting. The manual describes how to recognize cases of viral hemorrhagic fever, such as Ebola HF, and prevent further nosocomial transmission by using locally available materials and few financial resources. Similarly, a practical diagnostic test that uses tiny samples from patients’ skin has been developed to retrospectively diagnose Ebola HF in suspected case-patients who have died. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/ebola/qa.htm Medical Treatment Presently, no specific therapy is available that has demonstrated efficacy in the treatment of Ebola hemorrhagic fever.23 Ribavirin, an antiviral drug, has no demonstrable anti-Ebola activity in vitro and has failed to protect Ebola-infected primates. HIV inactivating protein cyanovirin-N displays potential anti-EBOV activity. CV-N binds N-linked high-mannose oligosaccharides on HIV glycoprotein gp120. Similar
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
oligosaccharide constituents of the EBOV envelope suggest susceptibility to CV-N inhibition. Initial results show CV-N antiviral activity against Ebola-Zaire both in vitro and in vivo12 During the 1995 outbreak in Kikwit, DRC, human convalescent plasma was used to treat 8 patients with proven Ebola disease. Only 1 of these patients died.
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}